Rescheduling Hydrocodone Combination Products Will Lead to More Responsible Use

Published Online: Monday, January 27, 2014
Follow Pharmacy_Times:
In this video, Mary Lynn McPherson, PharmD, professor and vice chair at the University of Maryland School of Pharmacy, argues that rescheduling hydrocodone combination products as Schedule II drugs will introduce limitations that will lead to more responsible prescribing of the drugs and monitoring of their use.
 
This is the ninth in a series of videos in which Dr. McPherson argues in favor of categorizing hydrocodone combination products as Schedule II drugs, and Jeff Fudin, PharmD, argues against doing so. (Drs. McPherson and Fudin were assigned to take these positions for a session at the American Society of Health-System Pharmacists 2013 Midyear Clinical Meeting in Orlando, and their arguments do not necessarily reflect their personal positions on the issue.)
 
These videos were filmed at the ASHP 2013 Midyear Clinical Meeting in Orlando.

Related Articles
The Drug Enforcement Administration has officially placed tramadol, a centrally acting opioid analgesic, into schedule IV of the Controlled Substances Act.
Creating and owning a student-specific website portfolio can help students stand out on their applications to pharmacy residency programs.
Ambulatory pharmacy practice will grow independent of community pharmacy practice, unless efforts are made to bring them closer together.
Fall and injuries in the elderly may be attributed to many popular prescription medications.
Latest Issues
$auto_registration$